Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEK | Q02763 | 9/20 | 0.54 |
| ▸ | KDR | P35968 | 7/20 | 0.54 |
| ▸ | BRAF | P15056 | 4/20 | 0.53 |
| ▸ | RAF1 | P04049 | 2/20 | 0.53 |
| ▸ | LCK | P06239 | 3/20 | 0.51 |
| ▸ | ABL1 | P00519 | 2/20 | 0.51 |
| ▸ | CSF1R | P07333 | 2/20 | 0.51 |
| ▸ | KIT | P10721 | 2/20 | 0.51 |
| ▸ | SRC | P12931 | 2/20 | 0.51 |
| ▸ | STK25 | O00506 | 1/20 | 0.51 |
| ▸ | CIT | O14578 | 1/20 | 0.51 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.51 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.51 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.51 |
| ▸ | PAK3 | O75914 | 1/20 | 0.51 |
| ▸ | STK10 | O94804 | 1/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | FYN | P06241 | 1/20 | 0.51 |
| ▸ | YES1 | P07947 | 1/20 | 0.51 |
| ▸ | LYN | P07948 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL974793 | 0.86 | TEK (0.70) | TEKKDRLCKAURKBAURKA | |
| SCHEMBL3323287 | 0.82 | BRAF (0.57) | TEKKDRBRAFRAF1LCK | |
| SCHEMBL973866 | 0.82 | TEK (0.75) | TEKKDRLCKABL1CSF1R | |
| SCHEMBL1265050 | 0.78 | TEK (0.70) | TEKKDRBRAFLCKABL1 | |
| SCHEMBL972856 | 0.76 | TEK (0.71) | TEKKDRLCKABL1CSF1R | |
| SCHEMBL973732 | 0.76 | TEK (0.62) | TEKKDRLCKAURKBAURKA | |
| SCHEMBL1266265 | 0.76 | KDR (0.81) | TEKKDRBRAFLCKABL1 | |
| SCHEMBL1265880 | 0.75 | TEK (0.81) | TEKKDRBRAFLCKABL1 | |
| SCHEMBL1264938 | 0.75 | KDR (0.81) | TEKKDRBRAFLCKABL1 | |
| SCHEMBL975286 | 0.75 | TEK (0.67) | TEKKDRLCKABL1CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868177-B2 | Multi-cyclic compounds and method of use | AMGEN INC. (US) | 2011-01-11 | — | — | US | claimed |
| EP-1994030-B1 | MULTI-CYCLIC COMPOUNDS AND METHOD OF USE | AMGEN INC (US) | 2010-08-25 | — | — | EP | claimed |
| US-20070213325-A1 | Multi-cyclic compound and method of use | AMGEN INC. (US) | 2007-09-13 | — | — | US | claimed |
| EP-1994030-B1 | MULTI-CYCLIC COMPOUNDS AND METHOD OF USE | AMGEN INC (US) | 2010-08-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213325-A1 | Multi-cyclic compound and method of use | TIE1, CDK1, CCNB1 | TEK 22/4885KDR 12/4885BRAF 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.